A subset of patients with alpha-gal allergy have gastrointestinal symptoms without skin changes or anaphylaxis, according to a clinical practice update published in the April issue of Clinical Gastroenterology and Hepatology.
Studies investigate the meaning of ‘multimorbidity’ and how much it costs us
The prevalence of multimorbidity, the co-occurrence of two or more chronic conditions, varies depending on exactly how it is defined. And the health care costs associated with many disease combinations cost more together than the sum of each individual disease. Those are the conclusions of two new studies, published April 4 in the open access journal PLOS Medicine, that broadly analyze the concept and costs of multimorbidity.
3D heart modelling offers non-invasive diagnosis and treatment options for aortic stenosis
The 3D printing of intricate anatomical structures has become increasingly sophisticated in line with advances in imaging technology, with the use of printed phantoms facilitating the more detailed manipulation of a simulated valve’s anatomy and control of blood flow behavior.
Study: Low-income people have heightened risk of death from heart attack in six health systems around the world
Despite vastly different health care systems, low-income patients across six different countries have mortality rates 10 to 20 percent greater than their high-income peers, according to a new study led by researchers from Harvard Medical School, the University of Texas Medical Branch, Galveston, ICES (formerly the Institute for Clinical Evaluative Sciences), and other international collaborators.
Study reveals epigenetic vulnerability of acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that causes uncontrolled accumulation of white blood cells. Because of the poor outcomes of this disease, researchers across the globe have been on the hunt for new ways to treat AML, while preserving normal blood development.
Strength training shown to reduce blood pressure when practiced with moderate to vigorous intensity 2–3 times a week
Strength training practiced with moderate to vigorous intensity two or three times a week is an effective way to mitigate arterial hypertension (high blood pressure), according to a Brazilian study published in the journal Scientific Reports.
Maharzad Hints new single, “Uja umozi”
By TROY MUKUPA
Lusaka based renowned singer and songwriter, Maharzad has told the Daily Nation Lifestyle that all is set for the release of his new single tagged “Uja umozi”. The single which was produced by the talented Rooster and features another renowned artist, Larry will be the singer’s first release for this year after the successful release of his love anthem hit song “Ayo” last year.
In an interview, Maharzad, real names, Julvedelmartmorious Malama Makasa, said the single announces his come back and the many hit songs he has lined up for the year 2023.
“After the release of ‘Ayo’ last year, I have been back in the studio cooking a song which will be titled ‘Uja umozi’ and it features Larry. We will be dropping the song on 28 March, 2023. The song was produced by Rooster. This is the same producer who worked on ‘Ayo’ my last release of 2022,” he said
The singer said he was grateful to God, Almighty, and all those that have stood with him through thick and think in his musical journey.
“To everyone who keeps encouraging me in my music career, thank you for the endless support. We are about to have a beautiful year,” he added
Dozens of brain proteins may play a critical role in body weight regulation
Genetic factors could contribute to up to 50%–75% of the variance in body mass index, or BMI, in the population.
Genetic analysis tool developed to improve cancer modeling
Lifestyle behaviors such as eating well and exercising can be significant factors in one’s overall health. But the risk of developing cancer is predominantly at the whim of an individual’s genetics.
Study finds that immunotherapy substantially increases survival of people with lymphomatoid granulomatosis
Results from a clinical trial conducted by researchers at the National Institutes of Health (NIH) show that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a type of immunotherapy, can live for decades after diagnosis. Lymphomatoid granulomatosis is a rare precancerous condition triggered by Epstein-Barr virus infection. Left untreated, the disease can progress to a high-grade form, which has a poorer prognosis and can quickly turn into an aggressive and fatal B-cell lymphoma.